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1. Introduction 
With estimated 1 080 000 diagnosed cases each year, which account for 1.1% of all deaths, 
colorectal carcinoma (CRC) ranks fourth in cancer-related deaths in both sexes worldwide 
(WHOSIS, 2008). In Europe, CRC is the third most lethal malignancy after lung and stomach 
cancers in men, and it ranks second after breast cancer in women (WHOSIS, 2008). 
CRC progression is characterized by increased growth of the primary carcinoma as well as 
lymphatic and haematogenic spread. The liver is often the first vascular bed in which 
disseminating colorectal cancer cells are trapped and therefore is affected in up to 10-20% of 
CRC patients at the time of presentation (Berney, et al., 1998). Another 40-50% of patients 
will eventually develop liver metastasis during the course of their illness, which is 
commonly the cause of death (Bentrem, et al., 2005, Stangl, et al., 1994, Sugarbaker, 1990). At 
present, liver resection is considered the treatment of choice for suited patients with 
colorectal liver metastases, offering a five-year survival rate of 25-44% (Choti, et al., 2002, 
Garden, et al., 2006, Zacharias, et al., 2004) to those 20-25% of patients with isolated liver 
metastasis (Adson, et al., 1984, Bismuth, et al., 1996, Fong, et al., 1999). Unfortunately, this 
procedure is feasible only in patients with no signs of irresectable extra-hepatic disease, 
whereas the median survival is only 9–19 months for patients with unresectable disease who 
receive systemic chemotherapy (de Gramont, et al., 2000, Giacchetti, et al., 2000, Meyerhardt 
and Mayer, 2005, Saltz, et al., 2000). 
However, the fact that CRC malignancy develops over a long period and can only be 
efficiently controlled if detected early provokes many efforts to better understand the 
neoplastic progression of this cancer. It is well known, that there is a continuous shedding of 
tumor cells from a primary CRC (Chambers, et al., 2002), but not all disseminated CRC cells 
develop into macrometastases. It was hypothesized that sub-populations of malignant cells 
evolve a genetic advantage to become “highly metastatic”. These clones are skilled to 
dissociate from the primary cancer, to intravasate into nearby blood and lymphatic vessels, 
to travel through the lymphatic and hematogenous systems, to survive the immune 
surveillance, to extravasate into distant tissues forming micrometastases, and to eventually 
colonize the target organ. 
In this cascade, the epithelial-mesenchymal transition (EMT), characterized by the loss of 
cell-to-cell adhesion and cell polarity (Thiery, 2003), plays a crucial role in different stages; 
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namely the dissemination of tumor cells as well as their intra- and extra-vasation (Gupta 
and Massague, 2006). Several known transcription factors, such as Snail, Slug, and Twist, 
were found to induce EMT on one hand and were implicated with tumor progression and 
metastasis on the other hand. In line with this, some downstream genes of these regulatory 
factors are responsible for cell-to-cell adhesion, specially E-cadherin and claudins. For 
example, up-regulation of Snail induces EMT and down-regulates the transcription of 
different tight junctions proteins (TJs), such as claudins and occludin (Findley and Koval, 
2009). Claudins (CLDNs) form the structural backbone of TJs, and comprise at least 27 
members of integral transmembrane proteins (Mineta, et al., 2011) ranging in size between 
20-27 kDa (Tsukita, et al., 2001). Recently, the altered expression of various claudins has 
been implicated in the progression of several human cancers (Cheung, et al., 2005, Hough, et 
al., 2000, Johnson, et al., 2005, Kominsky, et al., 2003, Long, et al., 2001, Michl, et al., 2001, 
Morin, 2005, Sanada, et al., 2006, Swisshelm, et al., 2005). In contrast to the published notion 
that claudin expression would decrease from tumorigenesis as tight junctions are lost 
during cellular transformation, the claudin status seems to change in a tissue-specific 
manner. For example, over-expression of Cldn2 has been correlated to colorectal cancer 
(Kinugasa, et al., 2007), whereas decreased Cldn7 expression has been reported in head and 
neck cancer (Usami, et al., 2006), invasive ductal breast carcinoma (Kominsky, et al., 2003), 
and metastatic breast cancer (Sauer, et al., 2005). In addition, Cldn3 and Cldn4 have been 
found repeatedly elevated in a variety of cancers including pancreatic ductal 
adenocarcinoma (Michl, et al., 2003) as well as ovarian, uterine, prostate, and breast cancers 
(Rangel, et al., 2003). In partial contrast, reduced expression of Cldn4 and Cldn5 was detected 
in hepatocellular and renal carcinomas (Soini, 2005). In CRC, both, up- and down-regulation 
of claudin4 expression have been described (de Oliveira, et al., 2005, Ueda, et al., 2007), as 
well as aberrant expression of Cldn1. 
Another type of cell connection has been named cell-to-extracellular matrix (ECM) contacts. 
On their disruption, they are presumably also implicated in tumor initiation. It is well 
known from each stage of malignant progression that tumor cells communicate with their 
microenvironment and thereby elicit responses from it. This microenvironment is mainly 
composed of tumor cells, extracellular matrix (ECM), stromal cells, immune cells and micro-
vessels (Farrow, et al., 2008, Jung, et al., 2002). The ECM is a scaffold of extracellular proteins 
that maintain tissue shape and provide the cellular compartment with structural support 
(Bosman and Stamenkovic, 2003). However, by influencing cell adhesion, migration, 
differentiation, proliferation and survival, the ECM is a remodeling network that contributes 
substantially to tumor progression and metastasis (Engbring and Kleinman, 2003, Ioachim, 
et al., 2002). Remodeling and deposition of the ECM is mostly regulated by a functional 
family of extracellular proteins known as matricellular proteins, which contribute to the 
structural integrity and composition of the ECM (Bornstein and Sage, 2002). One of the most 
important characteristics of matricellular proteins is their ability to manipulate the 
integration and turn-over of ECM (Bornstein and Sage, 2002, Kyriakides, et al., 2001). 
Furthermore, by playing a linker role between the ECM and the cell surface, matricellular 
proteins can also direct cell fate, survival, adhesion and motility (Bornstein and Sage, 2002, 
Brekken and Sage, 2000, Kyriakides, et al., 2001). 
Osteopontin (OPN) is an acidic extracellular matrix phosphoprotein of 298-amino acids 
secreted by a wide variety of cancers, which functionally favours tumor progression (Gao, et 
al., 2003, Weber, 2001). The secreted phosphoprotein binds to the integrins (e.g. ITG-ǂvǃ3 or 
ITG-ǂvǃ5) and CD44 families of receptors to propagate cellular signals (Agrawal, et al., 2002, 
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Yeatman and Chambers, 2003). In colorectal cancer, gene profiling studies have identified a 
positive correlation between advanced or metastatic colon tumors and abundant OPN 
expression (Wai and Kuo, 2004). Increased OPN expression is associated with tumor invasion 
or metastasis in cancers of the breast (Tuck, et al., 1999, Tuck, et al., 1998, Tuck, et al., 1997), 
stomach (Ue, et al., 1998), lung (Chambers, et al., 1996, Shijubo, et al., 1999), prostate 
(Thalmann, et al., 1999), liver (Gotoh, et al., 2002, Pan, et al., 2003), and colon (Agrawal, et al., 
2002, Yeatman and Chambers, 2003). Analysis of the OPN promoter has uncovered multiple 
consensus binding sites for known transcription factors (Hijiya, et al., 1994). 
The main aim of our experimental series was first to generate a model suited to be used for 
investigating the efficacy of new drugs (Eyol, et al., 2008, Seelig, et al., 2004, Wittmer, et al., 
1999). One of the few well-characterized animal models for hepatic colorectal cancer makes 
use of the rat CC531 cell line. Following topical injection of CC531 cells, liver metastases 
develop and their growth has been frequently used for studying effects of various anti-
cancer treatments (Marinelli, et al., 1991, Oldenburg, et al., 1994, Veenhuizen, et al., 1996). 
A second aim was to identify metastasis-related changes in gene expression in tumor cells, 
which differ from those in the primary tumor and probably play a crucial role in metastasis 
formation. Therefore, temporal changes in gene expression of CRC cells homing to the liver 
have been investigated using the above in vivo model, which is characterized by a defined 
onset of metastatic proliferation in rat liver following intraportal inoculation of CC531 
tumor cells. This, in turn, permits a close following of the time-dependent modulation of 
gene expression, as the tumor cells home into the liver and then grow to a lethal size. The 
technique of re-isolating these tumor cells from rat liver permitted to monitor for the first 
time the expression of several candidate genes in a time-dependent manner (Georges, et 
al., 2011). 
2. Description of the CC531 rat model 
2.1 Generation of the model 
Initially, the CC531 cell line was induced by treatment of WAG rats with 1,2 
dimethylhydrazine (DMH). Forty weeks after 6 weekly injections of 30 mg/kg DMH, a 
carcinoma originated in the ascending colon of injected WAG rats. After serial implantation 
to male rats, the resulting transplantable tumor was described to be moderately 
differentiated on histological examination (Marquet, et al., 1984). 
The majority of animal liver metastasis models available at that time was based on the 
subcutaneous or intraperitoneal injection of tumor cells (Venditti, et al., 1984). To imitate as 
closely as possible the physiological metastatic spread of colon cancer, different orthotopic 
models were developed. These included intraportal (Griffini, et al., 1997, Griffini, et al., 1996, 
Thomas, et al., 1993) and spleen injections (Fukumura, et al., 1997) resulting in a diffuse 
outgrowth of tumor cells in the liver, as well as implantation of tumor tissue fragments or 
cells under the Glisson‘s liver capsule giving a local, limited, and nodal growth pattern 
(Aguiar, et al., 1987, Bartkowski, et al., 1986, Kamphorst, et al., 1999). Quantification of 
tumor growth in the latter models is often done by measuring tumor diameters (Aguiar, et 
al., 1987, Bartkowski, et al., 1986, Kamphorst, et al., 1999), whereas the diffuse models 
couldn’t be quantified easily. To encounter this obstacle, many efforts have been made, 
including the 3-D reconstruction of metastases by consecutive serial sections (Griffini, et al., 
1997), counting tumor nodules in the liver (Thomas, et al., 1993), or the use of tumor specific 
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antibodies for immunohistological examination (Thomas, et al., 1993). These assays are 
protracted and allow only a gross grading of tumor mass or cytostatic-induced loss of tumor 
load in the liver. The use of reporter genes such as green fluorescent protein (GFP), 
luciferase, or β-galactosidase (GLB1) for tracing tumor cells has greatly facilitated both, 
quantification and localization at the single cell level (Chishima, et al., 1997, Dooley, et al., 
1993, Zhang, et al., 1994). In view of that, we aimed in our study to develop an orthotopic, 
diffusely growing liver metastasis model that can be used for diagnostic and therapeutic 
studies. For this purpose the CC531 rat colorectal cancer cell line with its natural homing 
into the liver was transfected by the Glb1 gene. 
The stable transfection of these cells with the Glb1 gene (Fig. 1) allowed quantitation of the 
tumor cell load at any time after implantation and hence a quick evaluation of the efficacy of 
therapy that can be used for diagnostic and therapeutic studies (Wittmer, et al., 1999). 
 
 
Fig. 1. CC531 cells growing in RPMI-1640 medium were stained by the activity of GLB1 
converting X-gal, a chromogenic substrate for GLB1. Parental cells (a) are compared with 
transfected (b) and subcloned (c) CC531 cells. The magnification is identical for all three 
photographs (see scale bar) 
2.2 Chemosensitivity of the model 
2.2.1 Chemoembolization of rat liver metastasis with microspheres and gemcitabine 
or irinotecan followed by evaluation of tumor cell load by chemiluminescence 
These experiments (Seelig, et al., 2004) were performed to determine the potential of hepatic 
artery chemoembolization (HACE) for reducing the tumor cell load. Seven days after the 
intraportal injection of CC531-lac-Z cells to male WAG/Rij rats, tumor positive animals 
were treated by intra-hepatic artery injection with solvent (n=17), degradable starch 
microspheres (DSM, 30 mg/kg; n=16), DSM plus 5-fluorouracil (5-FU; 90, 60, and 40 mg/kg; 
ntotal=43) or DSM plus gemcitabine (Gem; 100, 80, 50, and 10 mg/kg; ntotal=46). After 3 more 
weeks the experiment was terminated, the livers were weighed and the number of CC531-
lac-Z cells per liver was determined. Injection of DSM reduced the tumor cell load by 21% 
(T/C%=79), whereas the combination with 5-FU reduced tumor cell number more 
intensively at 60 mg/kg (T/C%=86), and 90 mg/kg (T/C%=19). None of these effects was 
significantly different from controls. The combination of DSM plus Gem was well tolerated 
and significantly (p<0.05) effective at 80, 50 and 10 mg/kg (T/C%= 16, 9 and 26, 
respectively; Fig. 2). 
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Fig. 2. Comparison of therapeutic efficacy: The mean tumor cell number of treated groups is 
given in percent of the respective control group (T/C* 100) 
Thus, the comparison of HACE with 5-FU or Gem showed that the efficacy of Gem in 
reducing the hepatic tumor cell load was significantly higher and its therapeutic ratio was 
greater than that of 5-FU. 
In a subsequent experiment, the effect of HACE with irinotecan was compared vs. 5-FU as a 
standard agent in rat liver metastasis (Saenger, et al., 2004). Briefly, 4 × 106 CC531-lac-Z cells 
were intraportally injected into male Wag/Rij rats. Irinotecan (10, 30 and 60 mg/kg) and 5-
FU (40, 60 and 90 mg/kg) were administered concomitantly with DSM (30 mg/kg) for 
temporary embolization. The tumor cell load was determined quantitatively using the 
chemoluminescence assay mentioned above. 
HACE with irinotecan induced a complete remission in 44% of the animals and the highest dose 
reduced the mean tumor cell load by 66% (P<0.001). In contrast, the highest dose of 5-FU caused 
a reduction of only 18% (P = 0.026) and altogether 23% complete remissions were observed in 
response to 5-FU (Table 1 and Fig. 3). Collectively, HACE with irinotecan had a greater effect 
than that of HACE with 5-FU, setting the basis for further investigation in clinical trials. 
 
Table 1. Results of hepatic arterial chemoembolization on tumor cell reduction 
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Fig. 3. The columns give the percentage of complete remissions (defined as 
chemoluminescence signal below that of a healthy control liver) in relation to the respective 
treatment group 
2.2.2 Combination treatment of CC531-lac-Z rat liver metastases by 
chemoembolization with pemetrexed disodium and gemcitabine 
The aim here was to evaluate the combination effect of pemetrexed disodium (MTA; Alimta; 
LY 231514) and gemcitabine (GEM) administered by hepatic artery and portal vein 
chemoembolization (HACE and PVCE) in our rat liver metastasis model (Rodenbach, et al., 
2005). After implantation of CC531 cells, MTA (30, 60 and 90 mg/kg) was administered 
locoregionally by PVCE and compared with repeated systemic intravenous injection. GEM 
(50 mg/kg) was also given locoregionally by HACE as well as systemically. All routes of 
administration were examined alone as well as in combination. Efficacy of treatment in 
terms of liver metastases burden was determined with the chemoluminescence assay. 
Locoregional administration by HACE with GEM was significantly more effective than 
systemic intravenous bolus treatment (P=0.03). Repeated systemic treatment with MTA 
yielded a slight reduction in tumor cell load that was significant vs. control at the medium 
and high doses (60 mg/kg, P=0.009; 90 mg/kg, P=0.046) but not vs. PVCE. The combination 
treatment of systemic (60 and 90 mg/kg) or locoregional (60 mg/kg) MTA with HACE 
using GEM (50 mg/kg) resulted in >80% tumor growth inhibition; this antineoplastic 
combination effect was maximally additive (Fig. 4). HACE with GEM was superior to 
systemic intravenous bolus treatment, while PVCE with MTA was ineffective. The optimal 
in vivo regimen of MTA (intravenous or PVCE) preceding GEM (HACE) resulted in a 
maximally additive tumor growth inhibition indicating that MTA and GEM can successfully 
be combined and favor further evaluation in patients. 
2.2.3 Chemoembolisation of rat colorectal liver metastases with drug eluting beads 
loaded with irinotecan or doxorubicin 
Chemoembolisation with drug eluting beads (DEBs) designed to deliver drug at the target 
over a prolonged period was tested as a new strategy to reduce the tumor burden of liver 
metastases (Eyol, et al., 2008). Accordingly, DEBs possessing anionic groups capable of 
ionically complexing with cationic drugs were synthesized by a suspension polymerization 
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Fig. 4. Summary of treatment effects; columns denote the respective therapeutic efficacy as 
quotient of treated and control values (T/C%) for (a) tumor cell number determined by ǃ-
galactosidase assay and (b) wet liver weight. White columns indicate the expected 
combination effect. Bars symbolize standard error of the mean 
method and were fractionated to produce an average size of 75 µm. The DEBs were loaded 
with the desired concentration of either doxorubicin hydrochloride or irinotecan 
hydrochloride prior to administration by immersion in the drug solution, yielding basically 
100% loading efficiency (Fig. 5). 
 
 
Fig. 5. Aspect of loaded and unloaded beads (a) Unloaded Beads; (b) Irinotecan DEB;  
(c) Doxorubicin DEB 
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After injection of CC531 cells as previously mentioned, DEBs loaded with irinotecan or 
doxorubicin were administered by single injection into the hepatic artery. The resulting 
reduction in liver tumor burden and the corresponding reduction in liver weight indicated 
significant anticancer activity (Fig. 6). 
Comparing the two agents, irinotecan appeared more advantageous because of its 
significant activity and excellent tolerability following administration at 2 dosages of either 
20 or 30 mg/kg. Doxorubicin showed a narrower activity window, being effective at 4 
mg/kg but ineffective at the lower dose of 2 mg/kg. Therefore, HACE with DEBs with 
either agent may have potential for treating patients with colorectal liver metastasis. 
 
 
Fig. 6. Gross pathological aspects of implanted control and treated livers using irinotecan 
DEB (top line) and doxorubicin DEB (bottom line) 
3. Search for genes that are involved in colorectal cancer liver metastasis 
To identify genes that are involved in the metastatic phenotype of CC531 cells, cDNA 
microarrays were used to analyze mRNA expression profiles of these cells for changes 
related to their homing into the liver. Briefly, CC531 cells were intraportally implanted into 
the liver of Wag-Rij rats and re-isolated after 3, 6, 9, 14 and 21 days (Fig. 7 (A-E)). For the re-
isolation purposes, the CC531 cells had been marked with stains for viable cells i.e. eGFP 
and RFP markers. 
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Fig. 7. (A-E). Photographs of rat liver taken at 3, 6, 9, 14 and 21 days after inoculation of 
CC531 cells, before re-isolation of the metastatic tumor cells 
3.1 The re-isolation technique of tumor cells, hepatocytes and Kupffer cells 
As mentioned before, the rats were kept for 3, 6, 9, 13 and 21 days after tumor cell 
implantation (Georges, et al., 2011). Then, the abdominal cavity was opened and a 22 G 
cannula was inserted into the portal vein, through which the liver was perfused with HBSS 
medium (20 ml/min, 37° C for 10 min). This medium was replaced with pre-warmed 
perfusion medium [125 ml HBSS containing CaCl2 1M, 0.1% pronase, 100 mg collagenase 
Type IV (Serva, Heidelberg, Germany), 37 ° C, for the following 10 min] to digest connective 
tissues. After getting the cells in suspension, they were filtered through a sterile filter (Cell 
strainer, 70 µm Nylon, BD, Germany) and centrifuged. The resulting cell suspension of liver 
and tumor cells was transferred into 50ml-tubes and layered carefully onto a Ficoll gradient 
medium (Amersham pharmacia Biotech AB, Uppsala, Sweden). 
 
 
Fig. 8. The density plot illustrates the CC531 population which was obtained by FACS sorting. 
The marker protein RFP was used for isolating CC531 cells without contaminating liver cells 
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After centrifugation, the tumor cells were obtained from the top of the interface and 
resuspended in RPMI medium. To obtain a high purity of isolated tumor cells, CC531 cells 
were subsequently isolated by fluorescence-activated cell sorting technology using red 
fluorescent protein (RFP) as marker (Fig. 8). 
Afterwards, the pure cells were pelleted and snap frozen at -80 °C. An aliquot of the cells, 
which were isolated on day 21, was used for re-culturing CC531 cells in vitro. These cells 
were propagated every 3 days, but two time points (14 and 22 days after tumor cell 
explantation) were chosen for subsequent microarray analysis, PCR, and Western blot. 
For the isolation of rat hepatocytes (HCs) and Kupffer cells (KCs), the same perfusion 
method was performed as described above. However, to separate parenchymal (PCs) from 
non-parenchymal cells (NPCs), cell suspensions were gently pelleted and the resulting 
pellet, containing mainly hepatocytes, was taken up in Maintenance-Medium without FCS. 
Trypan blue exclusion (1 part trypan blue: 2 parts cell suspension) was used for cell 
counting and assessing their viability. 4×107 hepatocytes with 95% viability were usually 
obtained from one rat liver. Afterwards, the 25%/50% two-step Percoll gradient was used to 
isolate Kupffer cells as pure as possible. 
 
 
Fig. 9. Down-regulation of Cldn1 and Cldn4 in CC531 cells homing into the liver. 
(A) Expression profile of claudins (1, 4) and Snail in CC531 cells as shown by microarray 
analysis. The values represent the gene expression in isolated metastasizing cells in 
comparison to the expression in cells growing in vitro. (B) The diagram represents the 
mRNA or protein expression levels in re-isolated CC531 cells in % of the expression 
detected in control cells (100%). Values were calculated using the pixel density of each 
PCR/or Western blot band normalized to the corresponding value of Ǆ-tubulin (Tubg1) or 
ERK2, respectively. (C) Expression of claudins (1, 4) in CC531 cells as shown by RT-PCR. 
Lane 1: control CC531 cells, lanes 2-6: CC531 cells isolated from the liver after 3, 6, 9, 14 and 
21 days, respectively, lanes 7, 8: CC531 cells re-isolated after 21 days and cultured in vitro for 
14 and 22 days, respectively. (D) Expression of CLDNs (1, 4) in CC531 cells as shown by 
Western blot. Lanes 1-5: CC531 cells isolated from the liver after 3, 6, 9, 14 and 21 days, 
respectively, lanes 6, 7: CC531 cells isolated after 21 days and cultured in vitro for 14 and 22 
days, respectively, lane 8: control CC531 cells 
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The cDNA microarray results showed that compared to control CC531 cells, claudin1 and 
claudin4 were among the ≥8-fold initially down-regulated genes (Fig. 9A). 
Interestingly, both genes were at first down-regulated with a nadir (8 or 11 fold down-
regulation) on day 6, followed by gradual up-regulation within the observation period. 
These results were confirmed with RT-PCR (maximum down-regulation of 80% on day 6 for 
both genes; Fig. 9B) and Western blot (specific bands below detection limit, >90% inhibition 
on day 6; Fig. 9C). It is noteworthy that the transcription repressor gene Snail showed an 
inverse modulation: an increased expression during the first week (up to 3.8 fold) with the 
peak of its expression corresponding to the nadir of Cldn1 and Cldn4 down-regulation  
(Fig. 9A). 
Next, two experiments were performed to explain the initial down-regulation of Cldn1 and 
Cldn4; these included co-culture of CC531 cells with isolated rat hepatocytes or Kupffer cells 
and the physical forces’ effect experiment: 
3.2 Co-culture/two compartment model 
Briefly, this model is based on a two-compartment system in which hepatocytes or Kupffer 
cells, plated in the lower compartment, are co-cultured with CC531 tumor cells growing in 
the upper compartment, with the two cell types being separated by a porous membrane (0.4 
µm pore size). This system, preventing a direct contact between the two compartments, 
allows the cells to be only indirectly influenced by molecules secreted from the cells in the 
other layer, respectively. 
No down-regulation effect on claudin expression was noticed, whereas both genes were up-
regulated after co-culture with hepatocytes (Fig. 10).  
 
 
Fig. 10. Expression of claudins (1, 4) in CC531 cells co-cultured for 24 to 72 h with Kupffer 
cells (KCs) and hepatocytes (HCs) in comparison to the housekeeping gene ү-tubulin as 
shown by RT-PCR 
3.3 Physical forces’ effect experiment 
2x106 CC531 cells were seeded in 25 cm2 flat-bottom flasks or into round 50 ml glass bottles 
(Steiner GmbH, Siegen Eiserfeld, Germany), which were rotated on a roller (Stovall Life 
Science Incorporated, Greensboro, NC USA) at a speed of 1rpm, preventing the cells from 
adhesion to each other and onto the flask bottom. After 24 h, the cells in flat flasks and half 
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of the cells in round bottles were harvested for PCR analysis; the other half of cells was 
seeded in flat flasks till the next day to investigate the influence of adhesion status on 
claudin expression and then harvested after determining their viability under the 
microscope. This procedure was done daily for 3 days after seeding the cells (Fig. 11). 
 
 
Fig. 11. Scheme indicating the experimental procedure for assessing the physical force’s 
effects 
As shown in Fig. 12, no change in Cldn1 expression was noticed either in CC531 cells 
growing continuously in flat flasks or in round bottles. On the contrary, Cldn4 mRNA 
expression was 2- and 1.8- fold higher in CC531 cells growing in flat flasks than their 
counterparts growing in round bottles at 48 and 72 h after seeding the cells, respectively.  
 
 
Fig. 12. Expression of claudins (1, 4) in CC531 cells harvested from round and flat flasks as 
shown by RT-PCR. Lanes 1, 3, 6: CC531 cells harvested from round bottles after 24, 48 and 
72 h, respectively. Lanes 2, 5, 8, 10: CC531 cells harvested from flat flasks after 24, 48, 72 and 
96 h, respectively. Lanes 4, 7, 9: CC531 cells harvested from flat flasks after being transferred 
from round bottles after 24, 48 and 72 h, respectively 
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Furthermore, transferring tumor cells from a non-adhesive state in round bottles to growing 
in flat bottom flasks for 24 h caused >2.5-fold increased expression of Cldn4, whereas no 
effect on Cldn1 expression was noticed. Accordingly, the physical conditions and the 
adhesion status of the cells affected differently the expression of Cldn1 and Cldn4, 
suggesting a direct relationship with the latter, but not with the former gene. 
3.4 Small interfering RNA (siRNA) knockdown experiments 
CC531 cells cultured in 6-well-plates were transfected with 100 nM siRNA or negative 
control using Lipofectamine 2000 (Invitrogen) following the manufacturer’s instructions. 
The cells were harvested at 24, 48 and 72 h after treatment. As shown by RT-PCR in Fig. 
13A, exposure to siRNA species directed against Cldn1 and Cldn4 caused reduced 
expression of mRNA to 24% and 15%, respectively. 
To further investigate a possible interdependence of these two genes, the expression of 
Cldn4 and Cldn1 was investigated in CC531si.Cldn1 cells and CC531si.Cldn4 cells, respectively. 
Expression of Cldn4 was down-regulated by 50% in tumor cells transfected with siRNA 
against Cldn1 (Fig. 13B), whereas inhibition of Cldn4 did not exert the same effect on Cldn1 
expression (data not shown). 
 
 
Fig. 13. (A) Down-regulation of claudins (1, 4) in CC531 cells after siRNA transfection as 
shown by RT-PCR. (B) Down-regulation of Cldn4 after 24-72 h in CC531si.Cldn1 cells 
(compared to CC531nonsense cells) as shown by RT-PCR 
The effect of Cldn1 and Cldn4 knockdown on cell growth (MTT assay), cell migration and 
colony formation (Adwan, et al., 2004, Georges, et al., 2011) was investigated as well. These 
in vitro experiments showed significantly increased migration and decreased clonogenic 
growth of tumor cells (p<0.05), but no effect on cell proliferation was noticed (Fig. 14). 
3.5 Expression of CLDN1 and CLDN4 in neoplastic human CRC tissues 
For the immunohistochemical (IHC) analyses of CLDN1 and CLDN4, 32 primary CRC 
tissue specimens with adjacent non-neoplastic tissue and 8 liver metastases were obtained 
from the Institute of Pathology, University of Heidelberg.  
The patients had a median age of 65 years and were classified into UICC stages ll (n=24) and 
IV (n=8) and graded as G2 (n=25) and G3 (n=7). The histopathological analysis revealed that 
the expression of CLDN1 was high in 91% (n=30) and that of CLDN4 in 85% (n=28) of all 
tumor specimens. Comparing the CLDN expression related to UICC stages, CLDN1 and 
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CLDN4 had significantly lower expression in stage IV than in stage ll (p=0.01 and p=0.05, 
respectively). In line with this, liver metastases showed lower expression of CLDN1 and 
CLDN4 than in the corresponding primary carcinomas (Fig. 15). This difference was 
significant for CLDN1 (p<0.05) but not for CLDN4. 
 
 
Fig. 14. Knockdown effects of Cldn1 and Cldn4 on cellular functions of CC531 cells . 
(A) Proliferation of CC531 cells in response to si.Cldn1 or si.Cldn4. (B) Increased migration of 
CC531 cells in response to si.Cldn1 or si.Cldn4. (C) Inhibition of colony formation of CC531 
cells in response to siRNA down-regulation of claudins (1, 4). (D) Inhibition of large colony 
formation of CC531 cells in response to siRNA down-regulation of Cldn1 or Cldn4. Data 
(n=3) are shown as means ± S.D. in % of nonsense-transfected cells, an asterisk denotes a 
significant difference to control cells (p<0.05) 
3.6 Correlation of CLDN4 or CLDN1 expression with prognosis in CRC patients 
For real-time PCR analysis, 67 sporadic CRC patients, who were admitted and underwent 
surgery in the time between (01/98 - 07/01) at the Municipal Hospital in Nürnberg 
(Department of Abdominal-, Thorax-, and Endocrine Surgery) were selected. 
The samples included in this study (for IHC and real-time PCR) were used based on the 
patients informed consent and approved by the Ethics Committee of the Universities of 
Heidelberg and Erlangen. 
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Fig. 15. Expression of CLDN1 and CLDN4 proteins in human CRC and liver metastasis 
tissues compared to normal mucosa as shown by immunohistochemistry. (A), (C) and (E) 
Expression of CLDN1 in normal mucosa, cancerous tissue and liver metastasis, respectively. 
(B), (D) and (F) expression of CLDN4 in normal mucosa, cancerous tissue and liver 
metastasis, respectively. Magnification x64 
The 67 CRC patients (42 men and 25 women) had an average age of 67 years and were 
classified into 4 UICC stages (I, n=11; II, n=25; III, n=20; IV, n=11). The expression levels of 
CLDN1 and CLDN4 were significantly correlated (P<0.05; Fig. 16A). No correlation between 
CLDN1 expression and age (p=0.19), tumor stage (p=0.88), or overall survival (p=0.2) was 
seen. With respect to CLDN4, also no correlation with age (p=0.69) or tumor stage (p=0.38) 
was noticed. However, the overall survival of CRC patients with high or low risk in relation 
to the median split of CLDN4 expression levels differed significantly according to the log-
rank test (p=0.018; Fig. 16B). Similarly, using a Cox model, there was not significant 
difference (p=0.07) between the low and high risk groups taking all stages together, whereas 
in patients with tumor stages l-lll, an elevated CLDN4 level was clearly associated with a 
less favorable prognosis (p=0.05; Fig. 16C).  
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Fig. 16. Correlation of CLDN1 or CLDN4 expression levels with prognosis in 67 CRC patients 
and with each other. (A) Scatterplot of the correlation between CLDN1 and CLDN4 expression 
levels assessed with the non-parametric correlation coefficient from Spearman (B) The Kaplan-
Meier plot represents the overall survival probability of CRC patients with high or low risk 
according to CLDN4 median split for overall survival. The log-rank test shows a significant 
difference (p=0.018) between the two groups. (C) The Kaplan-Meier plot demonstrates the 
overall survival probability of CRC patients with high or low CLDN4 expression, 
dichotomized into high and low risk groups by the CLDN4 median split for overall survival 
and after separating the stages into I-III and IV stages. The Cox model shows a significant 
association between CLDN4 elevated levels and less overall survival (p=0.05) 
3.7 OPN expression profile in CC531 cells ex-vivo 
After explanting the liver, a piece of liver containing tumor cells was resected and used for 
re-culturing CC531 cells (Georges, et al., 2010). These cells were cultured for three weeks 
and within this period passaged five times corresponding to 11, 13, 15, 18 and 21 days; 
respectively (passages 1-5). At these intervals the cells were investigated for their mRNA- 
and protein expression levels of OPN. 
At the mRNA level, Opn was up-regulated in CC531 cells explanted from the tumor. Over 
time, this Opn mRNA level gradually decreased till it disappeared after the third passage; 
i.e. after two weeks (corresponding to a reduction by 88%; Fig. 17, left). 
The OPN protein level, as shown by Western blot (Fig. 17, right), was first highly expressed 
but then down-regulated to minimally 5% within the next 15 days. A slight increase to 20% 
of the initial level was seen at the final passages 4 and 5. 
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Fig. 17. Expression of OPN on mRNA (left; RT-PCR) and protein (right; Western blot) levels. 
Lane 1: CC531 cells explanted from the tumor, lanes (2-6): CC531 cells after 11, 13, 15, 18, 
and 21 days; respectively 
4. Conclusion 
In conclusion, the model described in this chapter evolved in two main steps. First, for 
quantitation of tumor cell load, the CC531 cells had been marked with GLB1. This marker 
proved useful for the purposes of therapeutic studies with various anti-cancer agents. Using 
the GLB1-based chemoluminescence assay, it could be shown that the efficacy of hepatic 
artery chemoembolization with gemcitabine-microspheres was significantly higher than 
with 5-FU in reducing the tumor cell load. 
Also it was shown, that HACE with irinotecan-microspheres had a greater effect than that of 
HACE with 5-FU, setting the basis for further investigations in clinical trials. 
The same assay allowed us to evaluate the combination effect of pemetrexed disodium and 
gemcitabine administered by hepatic artery and portal vein chemoembolization in our rat 
liver metastasis model. These experiments showed that HACE/gemcitabine was superior to 
systemic intravenous bolus treatment, while PVCE/pemetrexed disodium was ineffective. 
Interestingly, a maximum additive tumor growth inhibition in vivo was noticed using a 
regimen of (intravenous or PVCE)/pemetrexed disodium preceding HACE/gemcitabine 
indicating that these two agents can successfully be combined and favor further evaluation 
in patients. 
The third set of therapeutic experiments, using HACE with drug eluting beads (DEBs) 
loaded with either doxorubicin hydrochloride or irinotecan hydrochloride showed that 
irinotecan is more advantageous because of its significant activity and excellent tolerability. 
In addition, HACE with DEBs with either agent may have potential for treating patients 
with colorectal liver metastasis. 
The CC531 tumor cells marked with GLB1 allowed a determination of the tumor cell load only 
after termination of the experiment. To further develop the model for determining the tumor 
cell load in living animals, other markers had to be introduced. These were eGFP and RFP, 
which enabled the next series of experiments that were related to liver metastasis genes. 
Realizing the fact that the most common cause of CRC-related death is the development of 
metastasis, especially into the liver, denotes the importance of identifying the metastasis-
related changes in tumor cells, which probably differ from those related to the primary 
tumor. Therefore, temporal changes in gene expression of CRC cells homing into the liver 
have been investigated using our in vivo model, which had been improved by eGFP and RFP 
markers. The intraportal inoculation of CC531 cells defines the onset of metastatic 
proliferation in rat liver. This, in turn, permits a close following of the time-dependent 
modulation of gene expression, as the tumor cells home into the liver and then grow to a 
lethal size. The technique of re-isolating these tumor cells from rat liver permits monitoring 
for the first time the expression of several candidate genes in a time-dependent manner. The 
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following cDNA microarray analysis showed that the initial phase of rat CRC cells homing 
into the liver involves a transient down-regulation of Cldn1 and in particular of Cldn4. The 
transcription repressor Snail, which regulates both claudins, was concomitantly up-
regulated during the early stages of metastasis before returning to normal expression levels. 
Silencing of Cldn1 and Cldn4 by siRNA increased migration and reduced colony formation, 
with these phenotypes consistent with metastatic homing. These experimental results were 
paralleled in human CRC tumor samples, which show increased CLDN1 and CLDN4 
expression in UICC stages I–III, and significantly reduced expression in stage IV and in liver 
metastasis. The results obtained with human specimens give first evidence of a modulated 
claudin expression similar to those in the rat model. However, a prospective study is needed 
to corroborate these results, taking into account separately the entities, colonic and rectal 
cancers. That research could be driven by our hypothesis that primary CRC tumors have an 
initial growth advantage from increased claudin expression, whereas metastasizing cells 
require a transient reduction in claudin expression to be liberated from the primary tumor 
and to then initiate metastatic growth in the liver. 
Based on these experiments we conclude that the CC531 colorectal cancer liver metastasis 
model in rats is attractive for translational research: it is suited for therapeutic studies as 
well as for identifying genes involved in colorectal cancer liver metastasis. 
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